Pharmaceutical

Risk adjusted net present value: What is the current valuation of Pfizer’s Idrebormilast?

Idrebormilast is a small molecule commercialized by Pfizer, with a leading Phase II program in Rosacea.

Jul 2, 2024 - 04:00
Idrebormilast is a small molecule commercialized by Pfizer, with a leading Phase II program in Rosacea.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Osive...

Next Article

The Gut-Hormone Connection: How Probiotics Support Women’s Hormones

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In early trial, drug appears to reduce harmful protein buildup in heart

STAT+: In early trial, drug appears to reduce harmful p...

May 21, 2023

STAT+: FDA approves Seres microbiome drug, as field advances

STAT+: FDA approves Seres microbiome drug, as field adv...

Apr 27, 2023

FDA grants breakthrough therapy status to Arrowhead’s plozasiran

FDA grants breakthrough therapy status to Arrowhead’s p...

Sep 12, 2024